TrakCel Revenue and Competitors
Estimated Revenue & Valuation
- TrakCel's estimated annual revenue is currently $12.6M per year.
- TrakCel received $Undisclosed in venture funding in October 2016.
- TrakCel's estimated revenue per employee is $155,000
- TrakCel has 81 Employees.
- TrakCel grew their employee count by 0% last year.
What Is TrakCel?
There are few other fields of medicine that require the level of mass customisation of production and careful orchestration of production pathways that Cell, Gene and Immunotherapies demand. A critical factor facing the industry is choosing technologies and partners that can deliver scale. From sample collection through logistics, manufacturing and final treatment, TrakCel's proven technology integrates and orchestrates every aspect of a clinical program and commercial product with comprehensive chain of custody, chain of identity and traceability throughout.keywords:Biotechnology,Healthcare
Number of Employees
Employee Growth %
TrakCel, a Cardiff, Wales-based supplier of cellular orchestration solutions supporting the cell and gene therapy industry, closed its latest funding round of undisclosed amount. The round was led by AmerisourceBergen and Labcorp (NYSE: LH). These funds will enable further transformation of Tr ...
The increasing number of cell and gene therapies in clinical development is evolving the supply chain into a 'supply cycle,' says TrakCel CEO, ...
Be The Match BioTherapies and TrakCel form a strategic partnership to integrate their offering for companies developing cell and gene ...
“Be The Match BioTherapies and TrakCel share the goal of ensuring that the next generation of cell and gene therapies can be developed ...
TrakCel, a Cardiff, Wales, UK-based cellular orchestration platform developer, received a multi-million dollar investment from San Francisco-based Telegraph Hill Partners. The company intends to use the funds for growth activities. Concurrent with the financing, Matt Mackowski, Tom Raffin M.D., ...
|2016-10-21||$Undisclosed||Undisclosed||Telegraph Hill Partners.||Article|